bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2000
-0.0060 (-2.91%)
At close: May 12, 2025, 4:00 PM
0.1983
-0.0017 (-0.85%)
After-hours: May 12, 2025, 7:46 PM EDT
Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Sep 1, 2022 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Maria Zannes |
Contact Details
Address: 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 United States | |
| Phone | 210 698 5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.13 |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer and Director |
| Steven Girgenti | Founder and Executive Chairman of the Board |
| James Michael Edwards C.P.A., M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary and General Counsel |
| Julie Anne Overton | Director of Communications |
| Dallas J. Coleman | Vice President of sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 8-K | Current Report |
| May 7, 2025 | 424B4 | Prospectus |
| May 5, 2025 | EFFECT | Notice of Effectiveness |
| May 5, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 2, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 29, 2025 | 10-K/A | [Amend] Annual report |
| Apr 22, 2025 | 424B3 | Prospectus |
| Apr 18, 2025 | EFFECT | Notice of Effectiveness |
| Apr 15, 2025 | DRS | [Cover] Draft Registration Statement |
| Apr 15, 2025 | PRE 14A | Other preliminary proxy statements |